Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SkinBioTherapeutics ( (GB:SBTX) ) has shared an announcement.
SkinBioTherapeutics, a Newcastle-based life science group specialising in skin health, builds on its proprietary SkinBiotix technology to develop cosmetic skincare and gut-skin axis supplements. Through partnerships such as Croda’s Zenakine-branded active ingredient and retail channels including Amazon and Superdrug, the AIM-listed company is expanding its presence while using acquisitions to add distribution, geographic reach and manufacturing capacity.
The company has appointed interim chief executive Rachel Parsonage to its board of directors after completing regulatory due diligence by its nominated adviser. Parsonage brings over 25 years’ experience leading consumer beauty and wellness businesses through growth and transition, and her early focus on engaging teams and partners comes as SkinBioTherapeutics awaits the outcome of an external investigation and prepares its half-year results, signalling a critical period for governance and strategic execution.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £11.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.
The score is primarily held back by continued losses and negative operating/free cash flows despite strong revenue growth. Technicals add further pressure due to a clear downtrend across major moving averages and bearish momentum indicators, while valuation is difficult to interpret positively given the negative P/E and lack of dividend support.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a UK-based life science company focused on skin health, built around its proprietary SkinBiotix platform developed with the University of Manchester. Its core pillars target the skin healthcare market through cosmetic skincare and gut-skin axis food supplements, supported by partnerships such as Croda’s Zenakine and retail distribution including Amazon and Superdrug.
The group is pursuing a consolidator strategy, acquiring complementary skincare and cosmetic businesses to broaden distribution, geographic reach and manufacturing capacity. Listed on AIM since 2017 and headquartered in Newcastle, it aims to funnel acquired capabilities into scaling its in-house brands, notably SkinBiotix and AxisBiotix, across consumer beauty and wellness segments.
Average Trading Volume: 4,637,815
Technical Sentiment Signal: Sell
Current Market Cap: £32.4M
See more insights into SBTX stock on TipRanks’ Stock Analysis page.